[Skip to Content]
[Skip to Content Landing]
Comment & Response
March 12, 2019

Errors in Analysis of Mean Deviations in Study of Photocoagulation vs Ranibizumab for Diabetic Retinopathy

Author Affiliations
  • 1Jaeb Center for Health Research, Tampa, Florida
JAMA. 2019;321(10):1007-1008. doi:10.1001/jama.2019.0374

To the Editor My coauthors and I recently undertook a review of the Original Investigation titled “Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial” published in the November 24, 2015, issue of JAMA.1 We found that incorrect data were reported for the baseline cohort in both eTables 11 and 12 in Supplement 1. In eTable 12, “Functional Outcome: Humphrey Visual Field Test-Mean Deviation,” the column headers were labeled incorrectly and the summary statistics for both HFA 30-2 and HFA 60-4 tests should have been presented in the original scale, instead of being weighted by the number of points in each test.